Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
1-Minute Consult

Should I start an SGLT-2 inhibitor in my patient with heart failure and chronic kidney disease?

Richard Sekerak, MD, Johanna Ben-Ami Lerner, MD, Pooja Prasad, MD and Megha Prasad, MD
Cleveland Clinic Journal of Medicine October 2023, 90 (10) 607-609; DOI: https://doi.org/10.3949/ccjm.90a.23004
Richard Sekerak
Columbia University Medical Center, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: [email protected]
Johanna Ben-Ami Lerner
NYU Langone, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pooja Prasad
Oregon Health Science University, Portland, OR
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Megha Prasad
Assistant Professor of Medicine, Columbia University Medical Center, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 90 no. 10 607-609
DOI 
https://doi.org/10.3949/ccjm.90a.23004
PubMed 
37783497

Published By 
Cleveland Clinic Journal of Medicine
Print ISSN 
0891-1150
Online ISSN 
1939-2869
History 
  • Published online October 2, 2023.

Copyright & Usage 
Copyright © 2023 The Cleveland Clinic Foundation. All Rights Reserved.

Author Information

  1. Richard Sekerak, MD⇑
  1. Columbia University Medical Center, New York, NY
  1. Address:
    Richard Sekerak, MD, Columbia University Medical Center, 630 W 168th Street, New York, NY 10032; ris9105{at}nyp.org
  1. Johanna Ben-Ami Lerner, MD
  1. NYU Langone, New York, NY
  1. Pooja Prasad, MD
  1. Oregon Health Science University, Portland, OR
  1. Megha Prasad, MD
  1. Assistant Professor of Medicine, Columbia University Medical Center, New York, NY

Cited By...

  • 1 Citations
  • Google Scholar
PreviousNext
Back to top

In this issue

Cleveland Clinic Journal of Medicine: 90 (10)
Cleveland Clinic Journal of Medicine
Vol. 90, Issue 10
1 Oct 2023
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Should I start an SGLT-2 inhibitor in my patient with heart failure and chronic kidney disease?
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Should I start an SGLT-2 inhibitor in my patient with heart failure and chronic kidney disease?
Richard Sekerak, Johanna Ben-Ami Lerner, Pooja Prasad, Megha Prasad
Cleveland Clinic Journal of Medicine Oct 2023, 90 (10) 607-609; DOI: 10.3949/ccjm.90a.23004

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Should I start an SGLT-2 inhibitor in my patient with heart failure and chronic kidney disease?
Richard Sekerak, Johanna Ben-Ami Lerner, Pooja Prasad, Megha Prasad
Cleveland Clinic Journal of Medicine Oct 2023, 90 (10) 607-609; DOI: 10.3949/ccjm.90a.23004
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Linkedin Share Button

Jump to section

  • Article
    • WHAT ARE THE CARDIOVASCULAR AND RENAL BENEFITS OF SGLT-2 INHIBITORS?
    • WHAT eGFR IS VALIDATED FOR SGLT-2 INHIBITORS IN CHRONIC KIDNEY DISEASE?
    • WHAT IS THE UNDERLYING MECHANISM OF ACTION OF SGLT-2 INHIBITORS?
    • WHEN SHOULD A CLINICIAN INITIATE SGLT-2 INHIBITORS?
    • WHAT ARE THE SIDE EFFECTS TO BE AWARE OF?
    • DISCLOSURES
    • REFERENCES
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Should I start an SGLT-2 inhibitor in my patient with heart failure and chronic kidney disease?
  • Google Scholar

More in this TOC Section

1-Minute Consult

  • Do I need to treat supine hypertension in my hospitalized patient?
  • What diagnostic tests should be done after discovering clubbing in a patient without cardiopulmonary symptoms?
  • Does my adult patient need a measles vaccine?
Show more 1-Minute Consult

Nephrology

  • What is the role for terlipressin in hepatorenal syndrome?
  • The new GFR equations: How will eliminating the race coefficient affect Black patients?
  • A useful gap
Show more Nephrology

Endocrinology

  • What is the role for terlipressin in hepatorenal syndrome?
  • The new GFR equations: How will eliminating the race coefficient affect Black patients?
  • A useful gap
Show more Endocrinology

Diabetes

  • What is the role for terlipressin in hepatorenal syndrome?
  • The new GFR equations: How will eliminating the race coefficient affect Black patients?
  • A useful gap
Show more Diabetes

Cardiology

  • What is the role for terlipressin in hepatorenal syndrome?
  • The new GFR equations: How will eliminating the race coefficient affect Black patients?
  • A useful gap
Show more Cardiology

Similar Articles

Subjects

  • Cardiology
  • Diabetes
  • Endocrinology
  • Nephrology

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire